China Next-Generation Sequencing Market
China Next-Generation Sequencing Market by Product Type (Consumables, Platforms, Bioinformatics), Technology (SBS, Nanopore), Workflow (Sequencing, Platforms, Bioinformatics), Application (Drug Discovery, Diagnostic, Agriculture) - Forecast to 2031
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The China next-generation sequencing market is projected to reach USD 2.84 billion by 2031 from USD 1.35 billion in 2026, at a CAGR of 16.0% from 2026 to 2031. Next-generation sequencing refers to advanced DNA and RNA sequencing technologies that enable rapid, high-throughput analysis of genetic material. These technologies are designed to deliver comprehensive genomic information and can be used across applications such as clinical diagnostics, oncology research, drug discovery, personalized medicine, and genomic studies.
KEY TAKEAWAYS
-
BY OFFERINGBy offering, the services segment is projected to register significant growth of 20.2% during the forecast period, supported by increasing demand for genomic research and clinical applications.
-
BY APPLICATIONBy application, the diagnostics segment is projected to register substantial growth of 16.4% in the China next-generation sequencing market during the forecast period, driven by rising cancer incidence and the adoption of targeted therapies using companion diagnostics.
-
PRODUCT, BY END USERAcademic & research institutes dominated the China next-generation sequencing market in 2025 with a share of 40.3%.
-
SERVICES, BY END USERAcademic & research institutes dominated the China next-generation sequencing market in 2025, with a share of 48.8%.
-
COMPETITIVE LANDSCAPE - KEY PLAYERSIllumina, Inc., Thermo Fisher Scientific Inc., and MGI Tech were identified as star players in the China next-generation sequencing market, given their strong market share and extensive offerings portfolios.
-
COMPETITIVE LANDSCAPE - STARTUPSNovogene Co., Ltd. and BGI Group have distinguished themselves among regional players by securing strong footholds in sequencing offerings and genomic research, underscoring their potential as emerging market leaders.
The China next-generation sequencing market is expanding rapidly, driven by advances in sequencing platforms, declining sequencing costs, and the growing adoption of precision medicine approaches. The increasing incidence of chronic diseases, expanding clinical applications in diagnostics, and increasing investment in genomic research and personalized treatment strategies are further accelerating demand for high-performance sequencing technologies across the country.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The China next-generation sequencing market is experiencing a phase of innovation and rapid adoption. Healthcare systems, research institutions, and pharmaceutical companies across China are witnessing advancements in sequencing technology development and regulatory frameworks. This progress aligns with emerging trends in precision oncology, genomic diagnostics, and personalized medicine. In China, the use of advanced sequencing platforms, long-read sequencing technologies, and integrated bioinformatics solutions is increasing among hospitals, research centers, and clinical laboratories. These technologies facilitate comprehensive genomic profiling, which promotes faster diagnosis, enables targeted treatment selection, and aligns with precision medicine and value-based care approaches. Government agencies and regulatory bodies are encouraging local manufacturing, the development of domestically produced sequencing platforms, and public-private research and development programs. These initiatives help shorten approval timelines and promote the adoption of clinically validated, cost-effective sequencing solutions tailored to the needs of the Chinese patient population.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Advancements in sequencing platforms and declining costs of sequencing technologies
-
Rising demand for precision medicine and increasing clinical applications in diagnostics
Level
-
High initial capital requirements for sequencing equipment and infrastructure
Level
-
Integration of artificial intelligence and machine learning for enhanced data management and analytics
Level
-
Ensuring data security, standardization, and managing complexity of genomic data analysis
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Advancements in sequencing platforms and declining costs of sequencing technologies
The continuous advancements in next-generation sequencing platforms, along with declining costs of sequencing technologies, are supporting greater adoption across China. Improved efficiency, higher throughput, and reduced per-sample costs are making sequencing more accessible to hospitals, research institutions, and pharmaceutical companies, which is increasing the use of genomic analysis in clinical diagnostics, drug development, and research applications.
Restraint: High initial capital requirements for sequencing equipment and infrastructure
High initial capital requirements for acquiring advanced sequencing equipment and establishing supporting infrastructure restrict the adoption of next-generation sequencing technologies in several healthcare facilities and research institutions across China. The substantial upfront costs, combined with ongoing maintenance and operational expenses, create financial challenges for organizations trying to implement comprehensive genomic testing programs.
Opportunity: Integration of artificial intelligence and machine learning for enhanced data management and analytics
The integration of artificial intelligence and machine learning technologies with next-generation sequencing presents significant growth opportunities in China. These advanced computational tools enable efficient processing, analysis, and interpretation of large-scale genomic datasets, improving diagnostic accuracy, accelerating research timelines, and supporting the development of personalized treatment strategies.
Challenge: Ensuring data security, standardization, and managing the complexity of genomic data analysis
Ensuring data security, achieving standardization across platforms, and managing the complexity of genomic data analysis remain key challenges in the China next-generation sequencing market. Organizations must invest in robust data protection measures, quality control systems, and skilled bioinformatics personnel to maintain reliability, compliance, and clinical utility of sequencing results.
CHINA NEXT-GENERATION SEQUENCING MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
BGI Genomics supported PUMCH-led UPWARDS, a national-scale rare disease genomics study in China. The collaboration focused on improving rare disease diagnosis using genomics. | Helped build a new diagnosis framework for rare diseases and supported broader clinical genomics adoption in China. |
 |
BGI Genomics worked with Chinese hospitals on a study showing high efficiency of severe thalassemia prevention using high-throughput sequencing. | Demonstrated the value of NGS in carrier screening and prenatal health, supporting the expansion of sequencing in maternal and population screening programs. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The China next-generation sequencing market is a collaborative ecosystem where sequencing platform manufacturers, reagent suppliers, bioinformatics companies, research institutions, and healthcare providers work together to develop and implement genomic technologies in clinical and research settings. Companies in the country supply a variety of sequencing platforms, consumables, software solutions, and related services. Contract research organizations, clinical laboratories, and academic institutions support the development, validation, and clinical implementation stages of sequencing applications. Ultimately, healthcare institutions, pharmaceutical companies, and research organizations in China utilize the developed sequencing technologies, benefiting from supportive government policies and expanding reimbursement frameworks.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
China Next-generation Sequencing Market, by Offering
The products segment holds the largest share of the China next-generation sequencing market. This dominance is driven by strong demand for sequencing instruments, consumables, and library preparation kits across clinical diagnostics and research applications. Increasing installation of sequencing systems, along with recurring usage of reagents and kits, continues to support the growth of the products segment in the country.
China Next-generation Sequencing Market, by Application
The diagnostic applications segment contributes significantly to market growth. This application segment is further categorized into cancer diagnostics, infectious disease diagnostics, reproductive health diagnostics, and other diagnostic applications. Cancer diagnostics represents a substantial segment of the China next-generation sequencing market. The increasing prevalence of cancer and the growing adoption of targeted therapies have propelled this segment to prominence in the country. Factors such as rising cancer incidence rates, expanding precision oncology programs, and increasing demand for companion diagnostics are driving the utilization of sequencing technologies for tumor profiling, treatment selection, and monitoring applications.
China Next-generation Sequencing Products Market, by End User
By end user, the academic & research institutes segment dominates the China next-generation sequencing products market. This is driven by extensive use of sequencing instruments and consumables across universities and national research centers, supported by large-scale genomics projects and continuous government funding for life science research.
China Next-generation Sequencing Services Market, by End User
By end user, the academic & research institutes segment dominates the China next-generation sequencing services market. This is driven by high outsourcing of sequencing and bioinformatics services by universities and research centers, supported by large-scale genomics projects, collaborative research programs, and the need for cost-effective access to high-throughput sequencing capabilities.
CHINA NEXT-GENERATION SEQUENCING MARKET: COMPANY EVALUATION MATRIX
Illumina, recognized as a leading player in the China next-generation sequencing market, offers a comprehensive portfolio that includes sequencing platforms, reagents, consumables, and bioinformatics solutions for clinical and research applications. The company maintains a strong presence in China through partnerships with local distributors, healthcare institutions, and research organizations. Another significant player in the China market is BGI Group, identified as an emerging leader. The company is strengthening its position by offering cost-effective sequencing services, developing domestically produced sequencing platforms, and expanding its capabilities in clinical diagnostics and genomic research.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 1.23 Billion |
| Market Forecast in 2031 (Value) | USD 2.84 Billion |
| Growth Rate | CAGR of 16.0% from 2026–2031 |
| Years Considered | 2024–2031 |
| Base Year | 2025 |
| Forecast Period | 2026–2031 |
| Units Considered | Value (USD Million/Billion) |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
|
| Country Covered | China |
WHAT IS IN IT FOR YOU: CHINA NEXT-GENERATION SEQUENCING MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Understanding adoption patterns for next-generation sequencing across Chinese healthcare and research institutions | Assessed sequencing technology adoption trends across key segments, including hospitals, clinical laboratories, pharmaceutical companies, and academic research institutions. | Helped clients align product & service offerings with institution-specific requirements, budget constraints, and application priorities. |
| Identifying local manufacturing capabilities and partnership opportunities | Mapped domestic sequencing platform manufacturers, reagent suppliers, bioinformatics companies, and service providers across China, with insights into production capabilities, technology partnerships, regulatory compliance status, and market positioning. | Supported market entry strategies, identified potential collaboration partners, and helped provide an understanding of competitive dynamics. |
RECENT DEVELOPMENTS
- November 2025 : PacBio supported Berry Genomics as a part of their partnership and announced that the Sequel II CNDx system has received Class III Medical Device Registration approval from the National Medical Products Administration (NMPA) in China.
- September 2023 : MGI Tech announced the approval of the DNBSeq-G99 sequencer as a medical device by China's National Medical Products Administration (NMPA).
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
This study on the china next-generation sequencing market employed secondary sources, directories, and databases to gather pertinent information. To gather and validate important qualitative and quantitative data and evaluate market growth prospects, in-depth interviews were conducted with many primary respondents including key industry participants, subject-matter experts (SMEs), C-level executives from key market players, and industry consultants. After estimating the china next-generation sequencing market using several research strategies, the size of the final market was obtained by triangulating data from primary research.
Secondary Research
The secondary sources referred to for this research study include publications from government sources. These include the Centers for Disease Control and Prevention (CDC), the US Food and Drug Administration (FDA), the World Health Organization (WHO), the American Cancer Society (ACS), the National Center for Biotechnology Information (NCBI), the National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), International Agency for Research on Cancer (IARC), National Institute for Infectious Diseases (IRCCS), Association for Clinical Genomic Science (ACGS), American Society of Human Genetics (ASHG), European Society of Human Genetics (ESHG), Asia Pacific Society of Human Genetics (APSHG), Nature Reviews Genetics, Nature Methods, Biotechnology and Biological Sciences Research Council (BBSRC), Organisation for Economic Co-operation and Development (OECD), Genome Research, National Cancer Institute (NCI), European Medicines Agency (EMA), Population Health Research Institute (PHRI), PubMed, World Bank, and the World Health Organization (WHO), among others. Secondary sources also included corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the china next-generation sequencing market, which was validated through primary research.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the china next-generation sequencing market scenario through secondary research. Several primary interviews were conducted with market experts from the supply side, such as C-level and D-level executives, operational managers, marketing & sales managers of key manufacturers, distributors, and channel partners of companies providing NGS; experts from the demand side, such as personnel from academic & research institutes, hospitals, clinics and diagnostic labs, pharmaceutical & biopharmaceutical industries, CROs, and other end users. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the next-generation sequencing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
NGS refers to non-Sanger-based, high-throughput DNA sequencing technologies. DNA strands can be sequenced simultaneously, yielding substantially more throughput and minimizing the need for fragment-cloning methods often used in the Sanger sequencing of genomes. NGS is fundamentally based on sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, and nanopore sequencing.
Stakeholders
- NGS instrument manufacturers, vendors, and distributors
- NGS service providers
- NGS bioinformatics/data analysis companies
- Research laboratories and academic institutes
- Venture capitalists and other government funding organizations
- Research and consulting firms
- Healthcare institutions (hospitals and diagnostic clinics)
- Pharmaceutical and biotechnology companies
- Academic and government research institutes
- Life science companies
Report Objectives
- To define, describe, and forecast the china next-generation sequencing market based on offerings, product type, platform technology, product workflow, product end user, service type, service workflow, service end user, application, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall china next-generation sequencing market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To profile the key players in the china china next-generation sequencing market and comprehensively analyze their platforms, reagents, kits, consumables, and services portfolios, market positions, and core competencies
- To track and analyze competitive developments such as product & service launches, expansions, agreements, and collaborations in the china next-generation sequencing market
- To benchmark players within the china next-generation sequencing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and service strategy
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This ReportPersonalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the China Next-Generation Sequencing Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Still Researching the
China Next-Generation Sequencing Ecosystem?
See the competitors, opportunity evaluation, and growth signals shaping it - Instantly!
Generate 15+ consulting-grade strategic intelligence outputs - from competitor analysis to board-ready strategy decks, tailored to your China Next-Generation Sequencing growth question.
Growth opportunities and latent adjacency in China Next-Generation Sequencing Market